^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MBRC-101

    i
    Other names: MBRC-101
    Associations

    News

    Trials
    Company:
    MBrace Therap
    Drug class:
    Microtubule inhibitor, EphA5-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    5ms
    First-generation and preclinical evaluation of an EphA5-targeted antibody-drug conjugate in solid tumors. (PubMed, J Clin Invest)
    Preclinical Good Laboratory Practice-compliant toxicology studies in rats and nonhuman primates demonstrated that MBRC-101 is well tolerated, with observed toxicities limited to known MMAE off-target effects. These findings establish EphA5 as a therapeutic target in cancer and support the translational development of MBRC-101 as a promising ADC candidate for clinical evaluation, currently in a first-in-human multicenter investigational trial for patients with advanced solid tumors (ClinicalTrials.gov, NCT06014658).
    Preclinical • Journal
    |
    EPHA5 (EPH Receptor A5)
    |
    MBRC-101
    10ms
    Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors (clinicaltrials.gov)
    P1/2, N=130, Recruiting, MBrace Therapeutics | Phase classification: P1 --> P1/2 | N=90 --> 130 | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Jul 2025 --> Jul 2026
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • EPHA5 (EPH Receptor A5)
    |
    HR positive • HER-2 negative
    |
    MBRC-101
    almost2years
    Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=90, Recruiting, MBrace Therapeutics
    Trial completion date • Trial initiation date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • EPHA5 (EPH Receptor A5)
    |
    HR positive • HER-2 negative • PTEN mutation + HR positive
    |
    MBRC-101
    2years
    Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=90, Recruiting, MBrace Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • EPHA5 (EPH Receptor A5)
    |
    HR positive • HER-2 negative
    |
    MBRC-101
    over2years
    Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=90, Not yet recruiting, MBrace Therapeutics
    New P1 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • EPHA5 (EPH Receptor A5)
    |
    HR positive • HER-2 negative
    |
    MBRC-101